These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 12373583)
1. Enzyme therapy for Pompe disease: from science to industrial enterprise. Reuser AJ; Van Den Hout H; Bijvoet AG; Kroos MA; Verbeet MP; Van Der Ploeg AT Eur J Pediatr; 2002 Oct; 161 Suppl 1():S106-11. PubMed ID: 12373583 [TBL] [Abstract][Full Text] [Related]
2. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells. Rossi M; Parenti G; Della Casa R; Romano A; Mansi G; Agovino T; Rosapepe F; Vosa C; Del Giudice E; Andria G J Child Neurol; 2007 May; 22(5):565-73. PubMed ID: 17690063 [TBL] [Abstract][Full Text] [Related]
3. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258 [TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Klinge L; Straub V; Neudorf U; Voit T Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117 [TBL] [Abstract][Full Text] [Related]
6. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988 [TBL] [Abstract][Full Text] [Related]
7. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405 [TBL] [Abstract][Full Text] [Related]
8. Pompe disease: current state of treatment modalities and animal models. Geel TM; McLaughlin PM; de Leij LF; Ruiters MH; Niezen-Koning KE Mol Genet Metab; 2007 Dec; 92(4):299-307. PubMed ID: 17826266 [TBL] [Abstract][Full Text] [Related]
9. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. Van den Hout JM; Reuser AJ; de Klerk JB; Arts WF; Smeitink JA; Van der Ploeg AT J Inherit Metab Dis; 2001 Apr; 24(2):266-74. PubMed ID: 11405345 [TBL] [Abstract][Full Text] [Related]
10. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts. Yang HW; Kikuchi T; Hagiwara Y; Mizutani M; Chen YT; Van Hove JL Pediatr Res; 1998 Mar; 43(3):374-80. PubMed ID: 9505277 [TBL] [Abstract][Full Text] [Related]
11. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. Kikuchi T; Yang HW; Pennybacker M; Ichihara N; Mizutani M; Van Hove JL; Chen YT J Clin Invest; 1998 Feb; 101(4):827-33. PubMed ID: 9466978 [TBL] [Abstract][Full Text] [Related]
12. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy. Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913 [TBL] [Abstract][Full Text] [Related]
13. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy. Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089 [TBL] [Abstract][Full Text] [Related]
14. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987 [TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888 [TBL] [Abstract][Full Text] [Related]
16. New insights into therapeutic options for Pompe disease. Richard E; Douillard-Guilloux G; Caillaud C IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928 [TBL] [Abstract][Full Text] [Related]
17. [Treatment of Pompe's disease with recombinant enzymes]. Van Hove JL Verh K Acad Geneeskd Belg; 1998; 60(4):347-57. PubMed ID: 9883081 [TBL] [Abstract][Full Text] [Related]
18. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Kroos M; Pomponio RJ; van Vliet L; Palmer RE; Phipps M; Van der Helm R; Halley D; Reuser A; Hum Mutat; 2008 Jun; 29(6):E13-26. PubMed ID: 18425781 [TBL] [Abstract][Full Text] [Related]
19. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. van Capelle CI; Winkel LP; Hagemans ML; Shapira SK; Arts WF; van Doorn PA; Hop WC; Reuser AJ; van der Ploeg AT Neuromuscul Disord; 2008 Jun; 18(6):447-52. PubMed ID: 18508267 [TBL] [Abstract][Full Text] [Related]
20. 24-months results in two adults with Pompe disease on enzyme replacement therapy. Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]